Read the latest from M8.
Feb 28, 2023
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico
Oct 03, 2022
moksha8 officially rebrands as M8 Pharmaceuticals
May 05, 2022
M8 Pharmaceuticals Announces approval of Mokbio® PS128™ in Mexico
Oct 05, 2021
M8 Pharmaceuticals Announces License of Exclusive Mexican Rights for Arlevert® from HENNIG ARZNEIMITTEL
Sep 14, 2021
M8 Pharmaceuticals Announces License of Exclusive rights for Diacomit® (Stiripentol) from Biocodex SAS
Aug 31, 2021
M8 Pharmaceuticals Announces License of Exclusive rights MED3000 from Futura Medical for Latin America
Jul 20, 2021
Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America
Jul 06, 2021
Marinomed Biotech AG Grants Exclusive Rights for Carragelose® to M8 Pharmaceuticals marketed locally as Barlo®
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.
moksha8 Brazil announces a strategic alliance with HRA Pharma to commercialize Lysodren as the first step to build an Oncology line in this Market
Mar 26, 2018
moksha8 Brazil has entered into a Promotion and Distribution Agreement with HRA Pharma to commercialize Lysodren in Brazil as the first step to build an Oncology line in this country. Lysodren (mitotane tablets) is an oral chemotherapeutic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma and until now the only product available in the market for this type of cancer.
Adrenocortical carcinoma (ACC) is a rare and aggressive tumor which peaks in incidence during the first and fifth decades of life. ACC has an estimated worldwide annual incidence of 2 cases per million overall. The highest reported annual incidence of pediatric ACC in the world occurs in Southern Brazil (3.4 per million) and is 10-15-fold higher compared to the United States (U.S.), where the annual incidence of pediatric ACC is 0.2-0.3 cases per million*.
With this alliance and the new addition to its portfolio, moksha8 expects higher revenue growth and this expansion into the Oncology therapeutic area allows it to achieve a greater presence in the markets in which it operates.
The deal is also relevant for moksha8 because with it, the company continues its philosophy to bring innovative treatments to improving the health and quality of life to patients around the world, especially with rare and aggressive disease as adrenal cortical carcinoma.
HRA Pharm, a fast growing, innovative healthcare company with headquarters in Paris, France, affirmed that this partnership allows them to expand the international reach of its Endocrinology and Rare Disease Division in different markets such as Europe, United States, Canada, Brazil and South Korea and strengthens its position as a key player in Adrenal Cortical Carcinoma.
The companies expect strong results and a possible expansion of the relationship in the South America Country.
**Adrenocortical Carcinoma in Adults and Children: A Population-Based Outcomes Study involving 1,623 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2012) Remedy Publications LLC Published 06 May, 2016